盛德鑫泰(300881) - 2024 Q1 - 季度财报

Revenue and Profitability - The company's revenue for Q1 2024 reached ¥593,855,819.50, representing a 94.89% increase compared to ¥304,720,757.99 in the same period last year[5] - Net profit attributable to shareholders was ¥49,784,880.18, a significant increase of 147.49% from ¥20,115,823.75 year-on-year[5] - Basic earnings per share increased by 150.00% to ¥0.45 from ¥0.18 in the same quarter last year[5] - The net profit for Q1 2024 reached CNY 52,317,258.97, representing a 160.0% increase from CNY 20,115,823.75 in Q1 2023[19] - Earnings per share (EPS) for Q1 2024 was CNY 0.45, compared to CNY 0.18 in the previous year, marking a 150.0% increase[19] Cash Flow and Financial Activities - The net cash flow from operating activities was -¥269,307,042.10, a decline of 785.21% compared to -¥30,423,053.65 in the previous year[5] - The cash inflow from operating activities was $416,286,692.47, an increase of 19.7% compared to $347,808,476.82 in the previous period[21] - The cash outflow from operating activities was $685,593,734.57, up 81.0% from $378,231,530.47 in the previous period[21] - The net cash flow from financing activities was ¥117,760,456.24, a 94.45% increase from ¥60,561,607.22 in the previous year, primarily due to the acquisition of a subsidiary[9] - The cash inflow from financing activities was $251,163,538.20, significantly higher than $87,100,000.00 in the previous period, marking a 187.5% increase[22] Assets and Liabilities - Total assets as of March 31, 2024, were ¥2,875,514,339.41, reflecting a 1.51% increase from ¥2,832,852,522.32 at the end of the previous year[5] - The total liabilities stood at CNY 1,767,897,071.20, slightly increased from CNY 1,767,161,876.97 year-over-year[17] - The total equity attributable to shareholders of the parent company was CNY 963,222,125.43, an increase from CNY 923,827,881.36 in the previous year[17] Research and Development - Research and development expenses increased by 60.58% to ¥18,708,730.08, attributed to the acquisition of a subsidiary[8] - Research and development expenses for Q1 2024 were CNY 18,708,730.08, compared to CNY 11,650,573.46 in Q1 2023, reflecting a 60.5% increase[18] Shareholder Information - The number of ordinary shareholders at the end of the reporting period was 9,442[11] - The top 10 shareholders collectively hold 20.25% of the company's shares, with significant stakes held by family members of the management[13] Investments - The company holds a 0.3287% equity stake in Jiangsu Quanxin Biomedical Co., Ltd. as part of its investment portfolio[14] - The company has invested in several biotech firms, including a 3.7256% stake in Shenzhen Hertz Life Science Technology Co., Ltd.[14] - The company is actively involved in the investment of various biotech startups, indicating a strategic focus on expanding its portfolio in the healthcare sector[14] Other Financial Metrics - The company reported a significant increase in contract liabilities, which rose by 292.49% to ¥16,522,159.03 due to increased advance payments[8] - The company reported a credit impairment loss of CNY 8,914,638.06, which increased from CNY 1,400,285.97 in the previous year[19] - The company received government subsidies amounting to ¥3,648,600.00 during the reporting period[6] - The company reported a total of CNY 12,097,653.57 in other receivables, slightly down from CNY 13,975,659.80[15] Inventory and Current Assets - The total current assets as of March 31, 2024, amounted to CNY 2,003,464,619.20, an increase from CNY 1,971,641,687.41 at the beginning of the period[15] - Accounts receivable increased to CNY 756,596,433.20 from CNY 615,666,823.10, reflecting a growth of approximately 22.83%[15] - Inventory rose to CNY 541,774,003.66, up from CNY 471,720,201.47, indicating an increase of about 14.81%[15] - The company's cash and cash equivalents decreased to CNY 308,968,732.32 from CNY 460,917,471.87, a decline of approximately 33%[15] Employee Compensation - The company reported a significant increase in employee compensation payments, totaling $51,085,760.07, compared to $23,670,195.03 in the previous period, representing a 115.5% increase[21] - The company experienced a cash outflow of $30,173,659.65 for taxes, which is a substantial increase from $4,076,155.09 in the previous period, indicating a 640.5% rise[21] Audit Status - The company has not yet audited the first quarter report, as indicated in the financial statements[23]